Subsequently, anti-ApoA-I IgG was shown (i) to be an independent predictor of poor cardiovascular outcome in several different populations at risk for CVD without concomitant autoimmune disease [14–17], and (ii) to provide incremental prognostic information over traditional risk factors for CVD [14–16, 18]. This evidence concerns the gene APOA1 and autoimmune disease.